RxDoctor Payments Data

Karina Gonzalez

Family · Houston, TXNPI 1104483775

Payments from drug & device makers

$8,138in general payments, 2019–2025

Across 309 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$558
  • Amgen$409
  • AbbVie$405
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$1,20015%
  • Food & beverage$6,93885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,138 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$71,857
TrulicityDulaglutide23$30,909
JardianceEmpagliflozin19$30,486
MounjaroTirzepatide21$29,191
FarxigaDapagliflozin Propanediol13$16,628
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,804
Albuterol Sulfate HfaAlbuterol Sulfate119$2,461
Levothyroxine Sodium130$1,407
Atorvastatin Calcium202$1,376
Methylprednisolone136$919
Gabapentin65$895
Duloxetine Hcl35$834
Losartan Potassium82$710
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst66$678
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide21$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,271$71,85736 claims
Lilly USA, LLCTrulicity, Mounjaro$558$60,10044 claims
Boehringer IngelheimJardiance$43$30,48619 claims
AstraZenecaFarxiga$1,156$16,62813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →